Quantcast

Latest Anthera Pharmaceuticals Inc. Stories

2011-07-29 07:00:00

HAYWARD, Calif., July 29, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the quarter ended June 30, 2011. Financial Results: Total operating expenses for the second quarter ended June 30, 2011 were $22.7 million, as compared to $7.9 million for the same period in 2010. For the six months ended June 30, 2011, total operating expenses were $41.3 million, as compared to $14.4 million for the same period in...

2011-06-08 15:00:00

HAYWARD, Calif., June 8, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 6,666,667 shares of its common stock, offered at a price of $7.50 per share. In addition, the Company has sold 1,000,000 shares of its common stock at a price of $7.50 per share pursuant to the underwriters' option to purchase additional shares, resulting in a total public offering of 7,666,667 shares....

2011-06-03 08:00:00

HAYWARD, Calif., June 3, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock, offered at a price of $7.50 per share. The offering is expected to close on or about June 8, 2011, subject to customary closing conditions. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of common stock to cover over-allotments, if...

2011-06-02 15:00:00

HAYWARD, Calif., June 2, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. Citi and Leerink Swann LLC are acting as joint book-running managers in the offering and...

2011-05-03 16:00:00

HAYWARD, Calif., May 3, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the quarter ended March 31, 2011. Financial Results: Total operating expenses for the first quarter ended March 31, 2011 were $18.7 million, as compared to $6.5 million for the same period in 2010. The increased operating expenses in the first quarter of 2011 were driven by expenses related to site initiations and the active enrollment...

2011-04-18 07:00:00

HAYWARD, Calif., April 18, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that enrollment in the Phase 3 VISTA-16 study of varespladib in Acute Coronary Syndromes (ACS) will continue based on the positive outcome of an interim biomarker analysis and review of available patient safety data. An independent statistician completed an analysis of various...

2011-02-24 16:00:00

HAYWARD, Calif., Feb. 24, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal auto-immune responses and inflammation, today announced Paul Truex, Anthera's President and Chief Executive Officer, will present at Citi's 2011 Global Health Care Conference in New York, NY on Tuesday, March 1, 2011, at approximately 1:30 pm Eastern Time. Citi 2011 Global Health Care Conference...

2011-02-23 16:00:00

HAYWARD, Calif., Feb. 23, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to discuss the analytical method of the upcoming VISTA-16 interim biomarker analysis and the expected timeline of the results. Conference Call Access: Date: February 28, 2011 Time: 5:00 pm Eastern Time...

2011-02-23 07:00:00

HAYWARD, Calif., Feb. 23, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced financial results and business highlights for the quarter and year ended December 31, 2010. Financial Results Total operating expenses for the fourth quarter ended December 31, 2010, were $12.9 million, as compared to $1.4 million for the same period in 2009. For the year ended December 31, 2010, total operating expenses were $35.8 million, as compared to $11.8 million for the...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related